Skip to main content
Figure 6 | Trials

Figure 6

From: WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

Figure 6

ADAPT Triple Negative trial design. Triple negative (HER2-/HR-) patients are treated with either nab-Paclitaxel and Gemcitabine or nab-Paclitaxel and Carboplatin for induction therapy, which is subject to randomization. Randomization is only applicable after HR and HER2 status are confirmed by central pathology. The randomized regimen is applied in the neoadjuvant setting for twelve weeks followed by surgery.

Back to article page

Trials

ISSN: 1745-6215